CSIMarket Company Name, Ticker, Competitors, else..
 
Rhythm Pharmaceuticals inc   (NASDAQ: RYTM)
Other Ticker:  
 
 
Price: $61.4800 $-0.49 -0.791%
Day's High: $62.645 Week Perf: -2.44 %
Day's Low: $ 60.70 30 Day Perf: 2.59 %
Volume (M): 666 52 Wk High: $ 69.89
Volume (M$): $ 40,958 52 Wk Avg: $54.25
Open: $61.97 52 Wk Low: $39.46



 Market Capitalization (Millions $) 3,877
 Shares Outstanding (Millions) 63
 Employees 111
 Revenues (TTM) (Millions $) 137
 Net Income (TTM) (Millions $) -174
 Cash Flow (TTM) (Millions $) 53
 Capital Exp. (TTM) (Millions $) 1

Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing therapies for rare genetic disorders of obesity. The company is committed to addressing the unmet medical needs of patients with these conditions and aims to improve their quality of life. Rhythm Pharmaceuticals utilizes a precision medicine approach to develop innovative therapies that target specific genetic mutations causing obesity-related disorders. Their research and development efforts are centered around a pipeline of potential treatments that aim to restore metabolic balance and help patients achieve sustainable weight loss and improvement in their overall health.


   Company Address: 222 Berkeley Street Boston 2116 MA
   Company Phone Number: 264-4280   Stock Exchange / Ticker: NASDAQ RYTM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.81%    
LLY   -6.91%    
REGN   -1.58%    
TEVA   -3.67%    
VRTX   -2.53%    
VTRS   -3.52%    
• View Complete Report
   



Partnership

Rhythm Pharmaceuticals Joins Forces with Raymond A. Wood Foundation to Launch Groundbreaking Research on Craniopharyn...

Published Tue, Mar 18 2025 11:57 AM UTC

In a significant stride towards understanding and addressing the debilitating impacts of fatigue in patients with craniopharyngioma, Rhythm Pharmaceuticals, a biopharmaceutical company focused on innovative therapies for rare neurological diseases, has announced a research collaboration with the Raymond A. Wood Foundation. This partnership aims to establish a comprehensive r...
Management Announcement

Rhythm Pharmaceuticals: Transformative FDA Approval Sparks Hope Amidst Revenue Challenges and Strategic Innovations,

Published Fri, Jan 10 2025 12:15 PM UTC

Rhythm Pharmaceuticals: Navigating Growth Amidst Challenges and BreakthroughsRhythm Pharmaceuticals, Inc. has made significant strides and faced notable challenges in 2024, as articulated in their preliminary financial announcements and recent FDA developments. This article aims to dissect the key facts surrounding the company s performance, product approvals, and its futu...
Management Announcement

Rhythm Pharmaceuticals IMCIVREE Receives FDA Approval for Pediatric Use Amidst Declining Revenue Concerns

Published Fri, Dec 20 2024 7:15 PM UTC

Rhythm Pharmaceuticals? New Milestone: A Beacon of Hope or a Signal of Trouble?BOSTON, Dec. 20, 2024 ? In a significant move that underscores the urgency in treating rare genetic disorders, Rhythm Pharmaceuticals, Inc. has officially announced FDA approval for its groundbreaking drug, IMCIVREE (setmelanotide), for patients as young as two years old. This approval extends th...
Clinical Study

Rhythm Pharmaceuticals Breaks New Ground Expanded UK Authorization for IMCIVREE and Promising Clinical Fin...

Published Tue, Dec 3 2024 11:00 AM UTC

Rhythm Pharmaceuticals, Inc. a biopharmaceutical company headquartered in Boston and traded on Nasdaq under the ticker RYTM, has announced an expanded marketing authorization for its drug, IMCIVREE (setmelanotide), in the United Kingdom. The United Kingdom s Medicines & Healthcare products Regulatory Agency (MHRA) has now sanctioned the use of IMCIVREE for treating obesity a...
Clinical Study

Rhythm Pharmaceuticals Reveals Promising Data at ESPE 2024 A New Dawn in Fighting Hypothalamic Obesity

Published Mon, Nov 18 2024 12:00 PM UTC

In an exciting announcement, Rhythm Pharmaceuticals has unveiled five impactful presentations at the upcoming European Society for Paediatric Endocrinology (ESPE) 2024, focusing on real-world data and therapeutic advancements related to setmelanotide. The data, particularly spotlighting pediatric patients with acquired or congenital hypothalamic obesity, offers a glimpse int...






Rhythm Pharmaceuticals Inc's Segments
Product revenue net    115.33 % of total Revenue
License revenue    -15.33 % of total Revenue
US Product revenue net    74.51 % of total Revenue
International Product revenue net    40.82 % of total Revenue
Single reportable segment    100 % of total Revenue
Single reportable Product revenue net    115.33 % of total Revenue
Single reportable License revenue    -15.33 % of total Revenue
Single reportable US Product revenue net    74.51 % of total Revenue
Single reportable International Product revenue net    40.82 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com